We are always concerned for keeping ourselves current and understanding our clients' businesses.
Av. San Juan 2964, 1er Piso Dpto B, (C1232AAY),
Ciudad Autónoma de Buenos Aires, Argentina
Phone/Fax 54-11-4308-2814
e - Mail : info@fabianbiali.com.ar
Español - English
News

Novedades

FEDERAL CHAMBER JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT.

The Federal Chamber ruled in favor of Laboratorios Beta on the trial against the alleged infringement of an Argentine patent related to the so called polymorph 2 of OLANZAPINE. Moreover, the Federal Chamber declared Argentine patent AR 002719B1 invalid. Fabian Biali actively acted as Technical Advisor for Laboratorios Beta on this subject.

LIST OF DRUGS CLAIMED IN ARGENTINE PATENTS IN FORCE

www.pharmapatents.com.ar

MODIFICATION OF PATENTABILITY  GUIDELINES ISSUED BY THE ARGENTINE PATENT OFFICE ON JULY 2013
New guidelines can be consulted  in http://www.inpi.gov.ar/pdf/Directrices2013.pdf

NEW GUIDELINES FOR THE EXAMINATION OF PATENT APPLICATIONS ON PHARMACEUTICAL INVENTIONS WERE APPROVED IN ARGENTINA.
According to Joint Resolutions 118/2012, 546/2012 and 107/2012 established by the Industry Ministry, the Health Ministry and the National Institute of Industrial Property of the Argentine Republic, “GUIDELINES FOR THE EXAMINATION OF PATENT APPLICATIONS ON PHARMACEUTICAL INVENTIONS” were approved. Among other things, “Provided that claims on polymorphs occur from the mere identification and/or characterization of a new crystalline form of a substance already known in the state of the art, even when they present pharmacokinetics differences or of stability with relation to the solid forms (amorphous and/or crystalline) with those known of the same substance, such claims are not acceptable” and that “Procedures of synthesis or manufacturing that are not by themselves novel or inventive, should be considered non-patentable as such, even though starting materials, intermediates or final products thereof are novel and inventive”.

FEDERAL CHAMBER  JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT.
The Federal Chamber ruled in favor of Laboratorios Richmond on the trial against the alleged infringement of an Argentine patent related to a process usable to manufacture GEMCITABINE.  Fabian Biali actively acted as Technical Advisor for Laboratorios Richmond on this subject.

FIRST INSTANCE JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT.
The first instance Judge ruled in favor of Laboratorios Richmond on the trial against the alleged infringement of an Argentine patent related to a process usable to manufacture DOCETAXEL TRIHYDRATE. Aventis started a lawsuit against several laboratories for such an infringement in the year 2003. Fabian Biali actively acted as Technical Advisor for Laboratorios Richmond on this subject.

DURING 2010, PATENTS THAT EXPLICITLY REFER TO THE FOLLOWING PHARMACEUTICAL COMPOUNDS IN THEIR TITLE OR ABSTRACT, HAVE BEEN GRANTED IN ARGENTINA:
Sorafenib, Apixaban, Rilvipirine, Icomucret, Lapatinib Ditosylate, Abacavir, Frovatriptan, Licofelone, Oxcarbazepine, Hydrocortisone, Aciclovir, Prucalopride Ribavirin, Albaconazole, Budesonide, Oxaliplatin, Strontium Ranelate, Nitasoxanide, Terbutaline, Vicriviroc, Discodermolide, Salbutamol, Ipratropium, Bapineuzumab, Romiplostim, Telmisartan, Esomeprazole, Apixaban, Metformin, Fenofibrate, Rosiglitazone, Cetamin, Perindopril, Abarelix, Pralnacasan, Bms-663513, Laropiprant, Lesogaberan, Talampanel, Verapamil, Moxifloxacin, Ivermectin, Albendazole, Levosimendan, Ibandronate, Omeprazole, Flavopiridol, Bicalutamide, Insulin Glulisine, Iron Polymaltose, Omeprazole, Epinastine, Perindopril, Vinblastine and Citalopram.

PROCEDURE TO EXCHANGE THE CHRONOLOGIC ORDER OF THE EXAMINATION OF PENDING ARGENTINE PATENTS APPLICATIONS.
On January 13th 2011, Resolution Nº 339/2010 was published in the Official Bulletin of the National Institute of Industrial Property (INPI), whereby a procedure to exchange the chronologic order of the examination of pending patents applications is admitted, in order to get that some of the most recent applications take the place of some of the old ones. Such procedure could be summed up as follows:
- Applications that may be subject to the exchange of positions in the chronologic order should correspond to the same applicant (individual or entity).
- Applications should pertain to the same subclass, according to the Strasbourg Agreement concerning the International Patents Classification.
- Dates to be taken into account for the exchange are those established for the payment of the substantial examination fee.
- Exchange request should be made in a special form required by the INPI, duly signed by the applicant or the agent thereof, accompanied by a copy of the authorized power of attorney.
- Each request shall be studied by the INPI and, it will eventually be accepted if all requirements are met, depending on the case.
- April 30th 2011 will be the due date for applicants to file the request for the exchange of chronologic order of the substantial examination of their invention patents applications.

FIRST INSTANCE JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT.

The first instance judge has handed down its judgement in favor of Laboratorios Richmond on the trial against alleged infringement of an argentine patent related to a process usable to manufacture GEMCITABINE. Eli Lilly & Company started a lawsuit for such an infringement in the year 2001. The judge, who heard the case, decided that the argentine company, Laboratorios Richmond, by commercializing their product GEZT containing GEMCITABINE, did not infringe the plaintiff’s rights on the patent. Fabian Biali actively acted as Technical Advisor for Laboratorios Richmond on this subject.

- During the year 2011, Fabian Biali will continue cooperating with the CONICET (National Council of Scientific and Technical Research of Argentina, in the preparation and drafting of patents applications developed by the researchers thereto.

-During the year 2011, Fabian Biali will give classes on “Introduction to Industrial Property” in the career of “Specialization on Industrial Biotechnology”, at the Faculty of Natural and Applied Sciences, Buenos Aires University.

 

 

 

 
News
Novedades

-FEDERAL JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT (OLANZAPINE).
-LIST OF DRUGS CLAIMED IN ARGENTINE PATENTS IN FORCE
-MODIFICATION OF PATENTABILITY  GUIDELINES ISSUED BY THE ARGENTINE PATENT OFFICE ON JULY 2013
-NEW GUIDELINES FOR THE EXAMINATION OF PATENT APPLICATIONS ON PHARMACEUTICAL INVENTIONS WERE APPROVED IN ARGENTINA
-FEDERAL JUDGEMENT IN FAVOR OF AN ARGENTINE LABORATORY IN A LAWSUIT FOR AN ALLEGED INFRINGEMENT TO AN INVENTION PATENT (GEMCITABINE).
-PROCEDURE TO EXCHANGE THE CHRONOLOGIC ORDER OF THE EXAMINATION OF PENDING ARGENTINE PATENTS APPLICATIONS.
More

 

Fabian Biali